

Prof. T. Josifova, Dr. K. Konieczka, Prof. J. Flammer (5/2024)

Effect of Ocufolin® forte in patients with neovascular AMD

Ocufolin® is a multivitamin preparation with L-methylfolate as the main component.

Study design: 27 eyes of 27 patients were treated with 3 aflibercept injections at one-month intervals. Of these, 15 patients additionally received 1 capsule of Ocufolin® forte per day (Ocufolin group), the other 12 patients served as a control group.


Study parameters: In addition to the standard examinations, the following tests were carried out at the start of the study and after 4 months: Determination of homocysteine in the blood, measurement of retinal venous pressure (RVP), OCTA imaging of the retina.

Inclusion criteria: nAMD patients who had been pre-treated with anti-VEGF between 6 and 23 times in the affected eye and had a homocysteine level of $>12 \mu\text{M/l}$ and an RVP $> 8 \text{ mm Hg}$ above the IOP.

Results: The ocufolin group had an average age of 76 and the control group of 77 years.

- The homocysteine blood level was significantly reduced in the ocufolin group, but not in the control group ($p < 0.001$).
- Retinal venous pressure decreased significantly more in both groups, but in the ocufolin group ($p < 0.001$). As the IOP was normal in all patients before and after the study, we show the ODF value in the graph. This indicates by how many mmHg the RVP is above the IOP.
- The CNV activity type 1 and 2 was reduced more in the ocufolin group than in the control group.


Effect of Ocufolin® forte



Conclusion

The additional intake of 1 capsule of Ocufolin® forte per day was well tolerated without side effects and significantly reduced the two important risk factors homocysteine and retinal venous pressure, CNV activity was reduced as well. We recommend further studies, also on patients in an earlier phase of the disease and also over a longer period of time.

Influence of the retinal venous pressure (RVP) on the perfusion pressure (PP) and thus indirectly on the blood flow to the retina and optic disc



This graphic symbolizes the arterial pressure entering the eye and the venous pressure exiting the eye in healthy people, people with low blood pressure (BP) or increased retinal venous pressure (RVP) or with both. The result is a reduction in the perfusion pressure and thus a reduction in the pressure gradient, i.e. the driving force Power of blood circulation.

Modified by: Konieczka K. Glaukopatient mit Verdacht auf Flammer-Syndrom. Klin Monatsbl Augenheilkd 2024; 241: 335



Increased RVP reduces blood flow to the retina and of the optic nerve head.